New algorithm doesn't require special catheters or 3D map of the heart to treat atrial fibrillation (Afib), reveals a new study.
New algorithm stops the catheter at the right target to treat atrial fibrillation (AFib), reports a new study. The findings of the study are published in the journal Cardiovascular Engineering and Technology. Patients with atrial //fibrillation or AFib experience chaotic electrical signals in the upper chamber of their heart (atria), which cause an irregular or quivering heartbeat (arrhythmia) that can lead to blood clots and heart failure. AFib also is a major cause of stroke and affects 33 million people worldwide.
‘New algorithm doesn't require special catheters or 3D map of the heart to treat atrial fibrillation (Afib). This technique stops the catheter at the right spot and identifies the source type with a 95.25 percent success rate and a 99 percent detection rate of scar tissue, regardless of scar size.’
Read More..
When medications and other treatments fail, specially trained cardiologists (electrophysiologists) turn to ablation, which involves a catheter that is gently guided to the heart to destroy malfunctioning tissue and scar the problematic areas. Prior to surgery, electrophysiologists require advanced 3D mapping of the heart to direct them to problematic areas, which is a laborious and time-consuming process.Read More..
This procedure also poses a number of challenges for physicians including low, long-term success rates, which requires a need for new techniques to successfully guide catheter movements and accurately detect AFib targets.
A team of researchers from Florida Atlantic University's College of Engineering and Computer Science and collaborators have developed the first algorithm that can locate patient-specific ablation targets within the atria that does not require specialized catheters or 3D electro-anatomic maps of the heart. The new algorithm - the iterative catheter navigation (ICAN) - is fundamentally different from existing approaches.
In the study, the researchers demonstrate that ICAN stops the catheter when it finds the AFib source and identifies the source type with a success rate of more than 95.25 percent using human Afib simulations.
The research team also tested the effectiveness of ICAN in the presence of fibrosis and patchy myocardial scars, which makes AFib source detection more challenging, with a 99 percent detection rate regardless of the scar size, using human Afib simulations.
Advertisement
"We have developed the first algorithm to localize atrial fibrillation sources by iteratively navigating a 20-electrode circular catheter that is routinely used for ablation procedures," said Behnaz Ghoraani, Ph.D., senior author, an assistant professor in FAU's Department of Computer and Electrical Engineering and Computer Science, and a fellow of FAU's Institute for Sensing and Embedded Network Systems (I-SENSE) and FAU's Brain Institute (I-BRAIN), two of the university's four research pillars.
Advertisement
Ghoraani and collaborators from the Rochester Institute of Technology, the University of Rochester Medical Center, and SUNY Upstate Medical Center, tested ICAN on realistic simulated data with several test cases of the rotor and foci-driven arrhythmias, which covered a broad range of activation patterns in 2D as well as 3D AFib simulations. They placed the catheter on 114,921 initial catheter locations across the simulated region for different rotor and foci mechanisms. In all cases, they modeled globally distributed fibrosis.
"Professor Ghoraani and her collaborators have developed a cutting-edge technique that has the potential to be a game-changer in how electrophysiologists treat atrial fibrillation with ablation," said Stella Batalama, Ph.D., dean of FAU's College of Engineering and Computer Science.
"The high performance of this algorithm is evident by the high source detection success rate. ICAN could significantly improve the success of patient-specific atrial fibrillation ablation and facilitate treating patients before the disease progresses to the permanent stage."
In addition, the researchers have demonstrated the feasibility of their study in a few human clinical Afib cases and plan to further validate ICAN in more patients. There are currently two patents pending for certain aspects of the algorithm.
Co-authors of the study are Prasanth Gaensan, a graduate student in FAU's College of Engineering and Computer Science; Elizabeth M. Cherry, Ph.D., Rochester Institute of Technology; David T. Huang, M.D., University of Rochester Medical Center; and Arkady M. Pertsov, Ph.D., SUNY Upstate Medical University.
Source-Eurekalert